
MeiraGTx Holdings (MGTX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.9M
Gross Profit
548.0K
28.45%
Operating Income
-41.6M
-2,159.71%
Net Income
-40.0M
-2,075.86%
EPS (Diluted)
$-0.51
Balance Sheet Metrics
Total Assets
224.0M
Total Liabilities
190.9M
Shareholders Equity
33.1M
Debt to Equity
5.77
Cash Flow Metrics
Operating Cash Flow
-29.4M
Free Cash Flow
-38.5M
Revenue & Profitability Trend
MeiraGTx Holdings Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 33.3M | 14.0M | 15.9M | 37.7M | 15.6M |
Cost of Goods Sold | 23.8M | - | - | - | - |
Gross Profit | 9.5M | - | - | - | - |
Gross Margin % | 28.5% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 119.5M | 103.8M | 85.7M | 66.7M | 33.9M |
Selling, General & Administrative | 54.2M | 47.3M | 46.6M | 43.8M | 44.2M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 173.7M | 151.1M | 132.3M | 110.5M | 78.1M |
Operating Income | -164.2M | -137.1M | -116.4M | -72.8M | -62.6M |
Operating Margin % | -493.4% | -977.8% | -730.9% | -193.0% | -401.9% |
Non-Operating Items | |||||
Interest Income | 4.1M | 2.3M | 777.0K | 212.0K | 1.3M |
Interest Expense | 13.3M | 13.2M | 4.9M | 288.0K | 139.0K |
Other Non-Operating Income | 25.5M | 64.0M | -9.1M | -6.7M | 3.4M |
Pre-tax Income | -147.8M | -84.0M | -129.6M | -79.6M | -58.0M |
Income Tax | - | - | - | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -147.8M | -84.0M | -129.6M | -79.6M | -58.0M |
Net Margin % | -444.1% | -599.5% | -814.2% | -211.0% | -372.6% |
Key Metrics | |||||
EBITDA | -147.4M | -121.1M | -107.0M | -64.7M | -57.1M |
EPS (Basic) | $-2.12 | $-1.49 | $-2.87 | $-1.80 | $-1.54 |
EPS (Diluted) | $-2.12 | $-1.49 | $-2.87 | $-1.80 | $-1.54 |
Basic Shares Outstanding | 69822353 | 56486525 | 45177857 | 44139655 | 37724189 |
Diluted Shares Outstanding | 69822353 | 56486525 | 45177857 | 44139655 | 37724189 |
Income Statement Trend
MeiraGTx Holdings Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 103.7M | 129.6M | 115.5M | 137.7M | 209.5M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 707.0K | 10.1M | 21.3M | 22.4M | 38.5M |
Inventory | 385.0K | - | - | - | - |
Other Current Assets | 2.0M | 1.0M | 1.7M | 2.4M | 4.6M |
Total Current Assets | 123.5M | 159.6M | 154.3M | 183.2M | 272.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | 70.5M | 78.4M | 76.0M | 73.5M | 57.5M |
Goodwill | 821.0K | 1.1M | 2.1M | 2.6M | 3.0M |
Intangible Assets | 821.0K | 1.1M | 2.1M | 2.6M | 3.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 3.0M | 3.0M | 1.4M | 1.4M | 1.0M |
Total Non-Current Assets | 146.2M | 167.1M | 163.9M | 136.9M | 91.1M |
Total Assets | 269.8M | 326.7M | 318.2M | 320.2M | 363.7M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 23.6M | 16.0M | 16.6M | 15.3M | 7.1M |
Short-term Debt | 4.1M | 4.2M | 3.9M | 3.4M | 2.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 903.0K | 1.3M | 6.6M | - | 24.0K |
Total Current Liabilities | 60.8M | 67.1M | 82.1M | 68.1M | 54.1M |
Non-Current Liabilities | |||||
Long-term Debt | 80.7M | 85.1M | 88.4M | 20.4M | 19.7M |
Deferred Tax Liabilities | - | 0 | 186.0K | 196.0K | 214.0K |
Other Non-Current Liabilities | - | - | 262.0K | 953.0K | - |
Total Non-Current Liabilities | 141.1M | 121.5M | 118.4M | 66.6M | 71.0M |
Total Liabilities | 201.9M | 188.6M | 200.5M | 134.8M | 125.1M |
Equity | |||||
Common Stock | 3.0K | 2.0K | 2.0K | 2.0K | 2.0K |
Retained Earnings | -702.0M | -554.2M | -470.2M | -340.6M | -261.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 67.8M | 138.2M | 117.7M | 185.4M | 238.6M |
Key Metrics | |||||
Total Debt | 84.8M | 89.3M | 92.2M | 23.7M | 22.2M |
Working Capital | 62.7M | 92.5M | 72.3M | 115.1M | 218.4M |
Balance Sheet Composition
MeiraGTx Holdings Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -147.8M | -84.0M | -129.6M | -79.6M | -58.0M |
Depreciation & Amortization | 12.7M | 13.7M | 8.6M | 7.9M | 4.2M |
Stock-Based Compensation | 25.2M | 27.7M | 28.6M | 20.8M | 18.4M |
Working Capital Changes | 44.9M | -3.3M | -2.7M | 24.2M | -32.4M |
Operating Cash Flow | -63.7M | -45.3M | -94.8M | -23.9M | -60.6M |
Investing Activities | |||||
Capital Expenditures | -5.0M | -20.2M | -45.0M | -55.2M | -34.9M |
Acquisitions | - | - | 0 | -6.5M | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 23.5M | -20.2M | -45.0M | -61.7M | -34.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | 0 | 0 | - |
Debt Issuance | - | - | 75.0M | 0 | - |
Debt Repayment | - | - | 0 | -1.0K | -23.0K |
Financing Cash Flow | 54.5M | 84.0M | 170.0M | -1.0K | 81.9M |
Free Cash Flow | -109.4M | -125.5M | -118.1M | -65.7M | -101.0M |
Net Change in Cash | 14.3M | 18.5M | 30.2M | -85.6M | -13.6M |
Cash Flow Trend
MeiraGTx Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.75
Forward P/E
9.75
Price to Book
19.41
Price to Sales
18.85
PEG Ratio
9.75
Profitability Ratios
Profit Margin
28.51%
Operating Margin
-2,159.71%
Return on Equity
-216.14%
Return on Assets
-37.28%
Financial Health
Current Ratio
1.52
Debt to Equity
244.35
Beta
1.24
Per Share Data
EPS (TTM)
$-2.31
Book Value per Share
$0.42
Revenue per Share
$0.47
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
mgtx | 650.6M | -3.75 | 19.41 | -216.14% | 28.51% | 244.35 |
Vertex | 120.5B | 32.82 | 7.31 | -5.64% | -8.91% | 10.00 |
Regeneron | 60.3B | 14.20 | 2.01 | 15.96% | 31.94% | 9.20 |
Denali Therapeutics | 2.0B | -5.30 | 1.76 | -35.21% | 0.00% | 4.59 |
Cg Oncology | 1.9B | -18.47 | 2.74 | -16.58% | 0.00% | 0.15 |
Amicus Therapeutics | 1.9B | -34.44 | 9.73 | -18.12% | -5.41% | 229.11 |
Financial data is updated regularly. All figures are in the company's reporting currency.